Status:
COMPLETED
A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Biologic medications have revolutionized the treatment of inflammatory diseases such as moderate-to-severe psoriasis. Though very effective with an excellent safety profile, patients may be apprehensi...
Detailed Description
The study will be conducted at the Wake Forest University Dermatology Clinic and on Amazon Mechanical Turk. Patients meeting the following characteristics will be eligible to participate: individuals ...
Eligibility Criteria
Inclusion
- Either diagnosed with psoriasis (ICD-9: 696.1) or a parent/caregiver of an individual diagnosed with psoriasis (ICD-9: 696.1).
- Subjects with a working knowledge of English.
Exclusion
- Already on or previously failed management attempts with an IL-23 inhibitor including ustekinumab, guselkumab, risankizumab, or Tildrakizumab, amongst others.
Key Trial Info
Start Date :
May 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 21 2019
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03465696
Start Date
May 14 2018
End Date
June 21 2019
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Baptist Health
Winston-Salem, North Carolina, United States, 27104